A Phase 2 interventional study of Maralixibat in Cholestatic Liver Disease, sponsored by Mirum Pharmaceuticals, Inc.. Completed at 17 sites in 8 countries. Open to participants aged 12 Months and older. Per ClinicalTrials.gov, last updated 2025-12-08.
Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Bile Duct Diseases with a site in United States — 2 open to participants now, 4 under way, none of them phase 3. Bile Duct Diseases · United States.
Among the 22 studies in Bile Duct Diseases with a site in United States, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2020, is one of 6 in phase 2, and was the 11th registered.
50 studies on the registry are indexed under Bile Duct Diseases; 13 are open to participants now.
Browse Bile Duct Diseases studies →2 of the 22 studies in Bile Duct Diseases with a site in United States are open now. Recruiting first, the newest first:
Orlando Health, Inc. · Sites in United States
Ages 18–100
Advanced Endoscopy Research, Robert Wood Johnson Medical School Rutgers University · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Bile Duct Diseases studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 12 Months and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 89 across 30 interventional studies indexed under Bile Duct Diseases.
Median enrollment 46 across the 12 interventional studies, 50 across the 9 observational. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 22 have an industry lead sponsor. The 10 most frequent:
Mirum Pharmaceuticals, Inc. is the lead sponsor of 40 studies on the registry; 7 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 11 (92%) have results posted.
Mirum Pharmaceuticals, Inc. has 7 studies filed under Bile Duct Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies in Bile Duct Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04637243Methodist Health SystemOutcomes From Treatment Liver and Bile Duct Diseases | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Bile Duct Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluate the long-term safety of maralixibat (MRX) in subjects with cholestatic liver disease including, but not limited to, Alagille Syndrome (ALGS), Progressive Familial Intrahepatic Cholestasis (PFIC) and Biliary Atresia.
This is a multicenter, open-label study of maralixibat in subjects diagnosed with cholestatic liver disease (including, but not limited to ALGS, PFIC or Biliary Atresia) who have previously participated in a maralixibat clinical study. All subjects received maralixibat in the previous studies and will continues to receive maralixibat in this study.
Inclusion Criteria Subjects will need to meet all criteria below to be considered eligible for the study.
Previously participated in a maralixibat study and with approval of the Medical Monitor. Previous participation is defined as:
Exclusion Criteria
A subject will be excluded from the study if any of the following exclusion criteria are met:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will all receive Maralixibat oral solution
Drug: Maralixibat
Maralixibat chloride oral solution orally twice daily (up to 1200\* mcg/kg/day), and according to indication. \*equivalent to 1140 mcg/kg/day maralixibat
Also known as: Formerly LUM001 and SHP625
Incidence of Treatment-Emergent Adverse Events
TEAE = Treatment-emergent Adverse Event; AESI = Adverse Event of Special Interest..
Time frame: From informed consent through approximately 4.5 years, including 30 days after last dose.
Long-Term Effect on Pruritus
Change from Baseline in Pruritus Severity assessed using the Clinician Scratch Score (CSS), a 5-point scale where 0 indicates no evidence of scratching and 4 indicates cutaneous mutilation with bleeding, hemorrhage, and scarring.
Time frame: From Baseline through Week 160, including Change from Baseline values.
Long-Term Effect on Serum Bile Acid Levels
Time frame: From Baseline through Week 160, including Change from Baseline values.
A total of 52 participants were enrolled at 17 sites across 8 countries (Australia, Belgium, Canada, France, Poland, Spain, United Kingdom and United States). Participants were previously on maralixibat for an average of 4 years before entering this study.
| Milestone | Maralixibat: ALGS | Maralixibat: PFIC |
|---|---|---|
| Started | 40 | 12 |
| Completed | 33 | 10 |
| Not completed | 7 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Liver transplant | 3 | 1 |
| Withdrew: Listed for liver transplant | 1 | 0 |
TEAE = Treatment-emergent Adverse Event; AESI = Adverse Event of Special Interest..
| Participants | Maralixibat: ALGS | Maralixibat: PFIC |
|---|---|---|
| At least one TEAE | 36 | 12 |
| TEAE ≥ 3 | 9 | 4 |
| Serious TEAE | 10 | 3 |
| Serious Treatment-Related Adverse Event | 0 | 0 |
| Serious Treatment-Related TEAE | 0 | 0 |
| TEAE Leading to Discontinuation of Study Drug | 3 | 1 |
| TEAE Leading to Death | 1 | 0 |
| Treatment-emergent AESI | 0 | 1 |
Change from Baseline in Pruritus Severity assessed using the Clinician Scratch Score (CSS), a 5-point scale where 0 indicates no evidence of scratching and 4 indicates cutaneous mutilation with bleeding, hemorrhage, and scarring.
| score on a scale | Maralixibat: ALGS | Maralixibat: PFIC |
|---|---|---|
| Long-Term Effect on Pruritus | -0.4 ± 0.89 | -0.3 ± 1.12 |
| µmol/L | Maralixibat: ALGS | Maralixibat: PFIC | Maralixibat: Overall |
|---|---|---|---|
| Long-Term Effect on Serum Bile Acid Levels | -15.948 ± 31.4239 | -82.647 ± 136.4354 | -59.994 ± 111.0334 |
Collected over The timeframe for reporting adverse events was from informed consent through approximately 4.5 years, including 30 days after last dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Maralixibat: ALGS | 1/40 (2.5%) | 10/40 (25%) | 36/40 (90%) |
| Maralixibat: PFIC | 0/12 (0%) | 3/12 (25%) | 12/12 (100%) |
| Event | Maralixibat: ALGS | Maralixibat: PFIC |
|---|---|---|
| Anal fissureGastrointestinal disorders | 0/40 | 1/12 |
| DyspepsiaGastrointestinal disorders | 0/40 | 1/12 |
| Condition aggravatedGeneral disorders | 0/40 | 1/12 |
| Lung abscessInfections and infestations | 0/40 | 1/12 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/40 | 1/12 |
| PruritusSkin and subcutaneous tissue disorders | 0/40 | 1/12 |
| Alagille syndromeCongenital, familial and genetic disorders | 2/40 | 0/12 |
| Arteriovenous malformationCongenital, familial and genetic disorders | 1/40 | 0/12 |
| Coarctation of the aortaCongenital, familial and genetic disorders | 1/40 | 0/12 |
| Abdominal massGastrointestinal disorders | 1/40 | 0/12 |
| Event | Maralixibat: ALGS | Maralixibat: PFIC |
|---|---|---|
| Corona virus infectionInfections and infestations | 9/40 | 9/12 |
| Upper respiratory tract infectionInfections and infestations | 4/40 | 5/12 |
| DiarrhoeaGastrointestinal disorders | 3/40 | 4/12 |
| NasopharyngitisInfections and infestations | 7/40 | 4/12 |
| Abdominal painGastrointestinal disorders | 6/40 | 3/12 |
| ToothacheGastrointestinal disorders | 2/40 | 3/12 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 4/40 | 3/12 |
| RashSkin and subcutaneous tissue disorders | 1/40 | 3/12 |
| PyrexiaGeneral disorders | 7/40 | 2/12 |
| ConstipationGastrointestinal disorders | 2/40 | 2/12 |
| Age, Customized(Participants) | Maralixibat: ALGS | Maralixibat: PFIC | Total |
|---|---|---|---|
| Age Categorical — 5 to 8 years | 8 | 4 | 12 |
| Age Categorical — 9 to 12 years | 18 | 7 | 25 |
| Age Categorical — 13 to 18 years | 9 | 1 | 10 |
| Age Categorical — > 18 years | 5 | 0 | 5 |
| Sex: Female, Male(Participants) | Maralixibat: ALGS | Maralixibat: PFIC | Total |
|---|---|---|---|
| Female | 19 | 7 | 26 |
| Male | 21 | 5 | 26 |
| Ethnicity (NIH/OMB)(Participants) | Maralixibat: ALGS | Maralixibat: PFIC | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 1 | 6 |
| Not Hispanic or Latino | 21 | 11 | 32 |
| Unknown or Not Reported | 14 | 0 | 14 |
| Race (NIH/OMB)(Participants) | Maralixibat: ALGS | Maralixibat: PFIC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 0 | 3 |
| White | 22 | 10 | 32 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 15 | 0 | 15 |
| Region of Enrollment(participants) | Maralixibat: ALGS | Maralixibat: PFIC | Total |
|---|---|---|---|
| Canada | 2 | 0 | 2 |
| Belgium | 2 | 0 | 2 |
| United States | 18 | 8 | 26 |
| Poland | 1 | 1 | 2 |
| United Kingdom | 8 | 3 | 11 |
| Australia | 4 | 0 | 4 |
| France | 4 | 0 | 4 |
| Spain | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2020 to primary completion in Sep 2024, 55 months.
Results were first posted in Dec 2025, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maralixibat